DUBLIN, IRELAND--(Marketwire - January 21, 2008) -
Alltracel Pharmaceuticals Plc
('Alltracel or the 'Company')
Statement re: Possible Offer
Monday, January 21st 2008, Dublin, Ireland and London, UK
The Board of Alltracel has noted the recent press speculation and confirms that
it has received a very preliminary approach from a third party which may or may
not lead to an offer being made for the entire issued share capital of
Alltracel.
It should be emphasised that discussions are at a very early stage and that
there is no certainty that they will lead to an offer.
The holder of 1% or more of any relevant securities in the Company may from the
date of this announcement have disclosure obligations under Rule 8.3 of the
Irish Takeover Panel Act, 1997, Takeover Rules 2001 to 2005, as applied, with
amendments by the European Communities (Takeover Bids (Directive 2004/25/EC))
Regulations 2006.
For Further Information Contact:
Dublin: Karen Muldowney Alltracel: +353 1 235 2162 press@alltracel.com
London: Deborah Scott/John Dineen Financial Dynamics: +44 207 831 3113
Des Carville Davy Corporate Finance: + 353 1 679 63 63
The Directors of Alltracel accept responsibility for the information contained
in this announcement. To the best of their knowledge and belief (having taken
all reasonable care to ensure that such is the case), the information contained
in this announcement for which they take responsibility is in accordance with
the facts and does not omit anything likely to affect the import of such
information.
This information is provided by RNS
The company news service from the London Stock Exchange